Condition category
Nutritional, Metabolic, Endocrine
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Type 2 diabetes is an inability to adequately regulate blood glucose levels and currently affects over 2 million people in England alone and this number is predicted to rise to over 4 million by 2025. In between having normal blood glucose levels and having type 2 diabetes, there exists a state where blood glucose levels are raised above the normal range but do not meet the criteria for type 2 diabetes; this has been called impaired glucose regulation (IGR). IGR can progress to diabetes so targeting those people with IGR provides an opportunity for preventing this disease. Research suggests that type 2 diabetes can be prevented or delayed in people with IGR through changes in lifestyle such as increasing physical activity. This study will investigate whether an intervention to support physical activity behaviour change and maintenance can lead to sustained increases in physical activity over four years & improvement in IGR as well as evaluating the effectiveness of the intervention when delivered at two levels of intensity.

Who can participate?
Participants will be 40-74 years of age (25-74yrs old if South Asian) with a diagnosis of IGR in the past five years.

What does the study involve?
Participants will be invited to attend three clinic visits; at baseline, 12 months and 48 months. These clinical visits involve Oral Glucose Tolerance Test (OGTT) together with other blood tests such as HbA1c, Urea & Electrolytes, Liver Function Tests, Full Lipid profile, Vitamin C & D, Insulin and inflammatory biomarkers & an optional genetics sample. Participants will also be asked to complete a questionnaire on diet, lifestyle and illness perception during their clinical visit. Participants will also be offered the option of having a scans to determine muscle & fat distribution throughout the body during the study. After their baseline visit participants will be randomly chosen to be in one of three groups: the control group (receive an advice leaflet), an intervention group with annual support (annual education sessions) or an intervention with ongoing behaviour change maintenance support (annual education session, telephone support and text messages/use of website).

What are the possible benefits and risks of participating?
All people taking part in the study receive information about reducing their risk of developing type 2 diabetes as well as results such as cholesterol levels, blood pressure and other health markers which are also passed on to your GP. Taking part involves minimal risk to the participant with only staff trained to take blood doing so to minimise any discomfort in this procedure.

Where is the study run from?
This study involves two centres, the Leicester Diabetes Centre in association with the University of Leicester who will be running the study together with the MRC Cambridge.

When is the study starting and how long is it expected to run for?
August 2013 to December 2019 (as of 04/10/2018)

Who is funding the study?
NIHR Health Technology Assessment Programme - HTA (UK)

Who is the main contact?
Professor Kamlesh Khunti

Trial website

Contact information



Primary contact

Prof Kamlesh Khunti


Contact details

Leicester Diabetes Centre
Leicester General Hospital
United Kingdom

Additional identifiers

EudraCT number number

Protocol/serial number

HTA 09/162/02

Study information

Scientific title

The PRomotion Of Physical activity through structured Education with differing Levels of ongoing Support for those with pre-diabetes (PROPELS): randomised controlled trial in a diverse multiethnic community



Study hypothesis

Can an intervention to support physical activity behaviour change lead to sustained increases in physical activity over four years in those with a high risk of type 2 diabetes.
We also aim:
1. To develop an intervention package to support maintenance of behaviour change.
2. To investigate the effectiveness of the intervention when delivered at two levels of intensity.
3. To investigate the effect of the intervention within White Europeans and South Asians subgroups.
4. To conduct an economic evaluation of both intervention conditions.

Ethics approval

Leicester Research Ethics Committee , 04/05/2012, ref:12/EM/0151

Study design

Multi-site randomised controlled trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting

GP practices

Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet




Control Group
Control subjects will receive a booklet detailing information on risk factors for type 2 diabetes mellitus (T2DM) and cardiovasular disease (CVD) and how physical activity can be used to prevent T2DM and CVD.

Intervention group with annual support
Participants in this group will receive the same booklet as group 1 and will also be offered a group−based structured educational programme aimed at promoting increased ambulatory activity by targeting perceptions and knowledge of diabetes risk, physical activity self−efficacy, barriers to physical activity and self−regulatory skills based on pedometer use. The programme will employ a person−centred approach to patient education that is based on self−management programmes for individuals with type 2 diabetes and prediabetes that have been developed and tested by our research group. The programme will be designed to be delivered to 5−10 participants by two trained educators and is 3.5 hours long. Participants will be offered annual followup support through the attendance of a 2 hour group based session aimed at revisiting the key messages of the initial structured education programme.

Intervention group with ongoing behaviour change maintenance support
Participants in this group will receive the same booklet as group 1 and the same structured education and annual followup group sessions as group 2. In addition, they will receive ongoing support in the form of phone calls 6 months after each education session, access to an interactive website and text messages on a regular basis.

Intervention type



Not Applicable

Drug names

Primary outcome measure

Change in ambulatory activity (steps per day) at 48 months

Secondary outcome measures

1. Time spent in sedentary, light, moderate and vigorous intensity physical activity assessed by accelerometer and selfreport (RPAQ)
2. Website use and text messages sent/received (intervention group 3 only)
3. Fasting and 2hour postchallenge glucose and HbA1c
4. Fasting lipid profile, fasting insulin, highly sensitive C-reactive protein, key adipokines (interleukin 6 and tumour necrosis factor alpha), urea & electrolytes (sodium, potassium, urea, creatinine) and liver function tests (Albumin, Total Bilirubin, Alkaline Phosphatase (ALP), Alanine Transaminase (ALT))
5. Markers of chronic inflammation and adipokines [Adiponectin, leptin, IL6, high sensitivity C-reactive protein (hsCRP)]
6. Vitamin C & D
7. Genetic analysis
8. Urine sample
9. Height
10. Body weight
11. Body Mass Index (BMI)
12. Body fat percentage
13. Waist circumference
14. Arm and leg length
15. Blood pressure
16. Medication status
17. Smoking status
18. Family history of disease
19. Muscular/skeletal injury
20. Illness perceptions
21. Selfefficacy
22. Self regulation
23. Quality of life
24. Depression and anxiety
25. Diet
26. Sleep
27. Body composition [Dual-energy X-ray absorptiometry (DEXA) & Magnetic resonance imaging (MRI)]

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Age 40-74 years or 25-74 years if South Asian
2. Diagnosed with Impaired Glucose Regulation (IGR) within the last 5 years

Participant type


Age group




Target number of participants

1308 participants aged 40-74 (or 25-74 years old if South Asian) and with a diagnosis of IGR in the past five years. In order to confirm participants eligibility we will need to screen more than this.

Participant exclusion criteria

1. Due to the nature of the intervention those unable to undertake ambulatory based activity will be excluded
2. Those diagnosed with diabetes
3. With screen detected diabetes at baseline
4. Pregnant women
6. Those with normal glycaemia with no previous record of IGR in the previous 5 years

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Leicester Diabetes Centre
United Kingdom

Sponsor information


University of Leicester (UK)

Sponsor details

University Road
United Kingdom

Sponsor type




Funder type


Funder name

NIHR Health Technology Assessment Programme - HTA (UK) ref: 09/162/02

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date


Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

2015 protocol in
2015 results in

Publication citations

Additional files

Editorial Notes

04/10/2018: The following changes have been made to the trial record: 1. The overall trial end date has been changed from 01/08/2018 to 31/12/2019 2. The recruitment end date has been changed from 01/08/2018 to 30/04/2015 3. The plain English summary has been updated 4. The intention to publish date has been added 21/12/2015: Publication reference added.